October 13, 2020

Second Covid vaccine trial paused over unexplained illness

The company declined to reveal any more details about the illness, citing the participant's

privacy.

A late-stage study of Johnson &Johnson's COVID-19 vaccine candidate has been paused while

the company investigates whether a study participant's “unexplained illness” is related to the

shot.

The company said in a statement on Monday evening that illnesses, accidents and other socalled

adverse events “are an expected part of any clinical study, especially large studies,” but

that its physicians and a safety monitoring panel would try to determine what might have

caused the illness.

The pause is at least the second such hold to occur among several vaccines that have reached

large-scale final tests in the US.

The company declined to reveal any more details about the illness, citing the participant's

privacy.

Temporary stoppages of large medical studies are relatively common. Few are made public in

typical drug trials, but the work to make a coronavirus vaccine has raised the stakes on these

kinds of complications.

Companies are required to investigate any serious or unexpected reaction that occurs during

drug testing. Given that such tests are done on tens of thousands of people, some medical

problems are a coincidence. In fact, one of the first steps the company said it will take is to

determine if the person received the vaccine or a placebo.

The halt was first reported by the health news site STAT.

Final-stage testing of a vaccine made by AstraZeneca and Oxford University remains on hold

in the US as officials examine whether an illness in its trial poses a safety risk. That trial was

stopped when a woman developed severe neurological symptoms consistent with transverse

myelitis, a rare inflammation of the spinal cord, the company has said. That company's testing

has restarted elsewhere.

Johnson & Johnson was aiming to enrol 60,000 volunteers to prove if its single-dose approach

is safe and protects against the coronavirus. Other vaccine candidates in the US require two

shots.


https://www.tribuneindia.com/news/health/second-covid-vaccine-trial-paused-overunexplained-

illness-155100

Pfizer modifies protocol for virus vaccine study

Diversity aimed at providing information on how safe and effective the experimental vaccine

is in people of different ages and backgrounds

Drugmaker Pfizer has again modified the protocol for its late-stage study of its vaccine against

the new coronavirus, this time to include more young participants.

The company said on Monday that it's received permission from the Food and Drug

Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine

study.

New York-based Pfizer originally planned for 30,000 participants, but in September expanded

that to 44,000 people. That increase was made to boost diversity in the trial population,

specifically by including 16- and 17-year-old teens, as well as stable patients with some

common chronic infections: hepatitis B, hepatitis C and HIV.

Pfizer's trial also includes significant numbers of Hispanic, Black, Asian and Native American

participants, plus many people aged 56 through 85. The diversity is aimed at providing

information on how safe and effective the experimental vaccine is in people of different ages

and backgrounds.


https://www.tribuneindia.com/news/health/pfizer-modifies-protocol-for-virus-vaccine-study-

155095

Study: Sars-CoV-2 can stay on touchscreens, currency for weeks



The Indian Express

 

September 25, 2020

J&J vaccine in phase-3 trails


 The Indian Express

Panacea Biotec completes Phase I/II study of DengiAll vaccine

DengiAll is a single-dose live-attenuated tetravalent vaccine

Drug firm Panacea Biotec on Thursday said it has successfully completed Phase I/II clinical study to evaluate the safety and immunogenicity of its DengiAll vaccine.

According to the World Health Organization, dengue represents one of the 10 biggest global health threats and it is critical to have access to a safe and effective vaccine candidate that can reduce the devastating impact of dengue fever in endemic regions, Panacea Biotec said in a BSE filing.

DengiAll is a single-dose live-attenuated tetravalent vaccine. “Lt induced robust, balanced neutralising antibody responses against all the four dengue virus serotypes”, it said.

“DengiAll’s Phase I/II study results are even more important in the context of the COVID-19 pandemic. Co-infection of dengue and COVID-19 in a dengue-endemic India may complicate approach to treatment and strain health care infrastructure,” Panacea Biotec MD Rajesh Jain said.

The company has already approached the Drugs Controller General of India (DCGI) to seek accelerated review of its data to bring DengiAll to market quickly and reduce burden on the country’s healthcare infrastructure, he added.

Shares of Panacea Biotec were trading at Rs 196.80 per scrip on BSE, up 4.99 percent from its previous close. 

https://www.tribuneindia.com/news/health/panacea-biotec-completes-phase-i-ii-study-of-dengiall-vaccine-145904